^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JNJ-6665

    i
    Other names: JNJ-74856665, JNJ74856665, JNJ-6665
    Associations

    News

    Trials
    Company:
    J&J
    Drug class:
    DHODH inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=153, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-6665
    9ms
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=155, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Dec 2023 --> Jul 2024
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-6665
    over1year
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=157, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2023 --> Dec 2023 | Trial primary completion date: Feb 2023 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-6665
    2years
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=157, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2024 --> Aug 2023 | Trial primary completion date: Sep 2023 --> Feb 2023
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-6665
    2years
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=157, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=281 --> 157
    Enrollment closed • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-6665
    over2years
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=281, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2024 --> Dec 2024
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-6665
    3years
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=281, Recruiting, Janssen Research & Development, LLC | N=120 --> 281 | Trial completion date: Sep 2023 --> Jun 2024
    Enrollment change • Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-6665
    over3years
    [VIRTUAL] JNJ-74856665, a novel DHODH inhibitor, mediates potent anti-leukemic activity and differentiation in vitro and in vivo (AACR 2021)
    Combination of JNJ-74856665 with azacitidine in vivo demonstrated lack of antagonism in the anti-leukemic activity.The results described herein demonstrate that JNJ-74856665 exerts potent anti-leukemic activity in vitro and in vivo and warrant further investigation. To that end, a phase 1 clinical trial assessing the safety and efficacy of JNJ-74856665 in patients with AML and MDS is planned to initiate shortly.
    Preclinical
    |
    CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M)
    |
    azacitidine • JNJ-6665